Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214486 · ClinicalTrials.gov registry record · NA
Measurement of Plasma and Intracellular Concentrations of Raltegravir
A NA study, sponsored by University of Nebraska.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01214486 is a NA study that has completed, run by University of Nebraska. The registered enrollment target is 12 participants.
The verdict
NCT01214486, a NA study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).
Interventions
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-10-01 |
| Est. Completion | 2011-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214486
The ClinicalTrials.gov registry entry for NCT01214486 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir is the first listed.
NCT01214486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214486 about?
NCT01214486 is a clinical study titled "Measurement of Plasma and Intracellular Concentrations of Raltegravir". The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).
What is the current status of trial NCT01214486?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2010-10-01. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT01214486?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01214486?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.